Abstract
Aim: Patient-reported symptoms, functioning and overall quality of life (QoL) were compared between dacomitinib and gefitinib in ARCHER 1050. Patients & methods: Patients (n = 448) with advanced EGFR mutation-positive non-small-cell lung cancer completed the EORTC-QLQ-C30 questionnaire and its lung-specific module, LC-13. Mean scores over time were analyzed using a mixed model for repeated measures. Results: Both treatments showed early improvement in disease-related symptoms that was maintained during treatment. Treatment-related diarrhea and sore mouth decreased following dose reduction with dacomitinib. There were no clinically meaningful changes in functioning and overall QoL in either treatment group. Conclusion: Longer treatment duration, enabled by dose reduction, allowed patients on dacomitinib to improve treatment-related symptoms and maintain functioning and overall QoL for longer than gefitinib.
Keywords:
dacomitinib; health-related quality of life; non-small-cell lung cancer; patient-reported outcomes.
Publication types
-
Clinical Trial, Phase III
-
Multicenter Study
-
Randomized Controlled Trial
MeSH terms
-
Activities of Daily Living
-
Administration, Oral
-
Adult
-
Aged
-
Carcinoma, Non-Small-Cell Lung / complications
-
Carcinoma, Non-Small-Cell Lung / drug therapy*
-
Carcinoma, Non-Small-Cell Lung / genetics
-
Carcinoma, Non-Small-Cell Lung / mortality
-
Dose-Response Relationship, Drug
-
Drug Administration Schedule
-
ErbB Receptors / genetics
-
Female
-
Gain of Function Mutation
-
Gefitinib / administration & dosage
-
Gefitinib / adverse effects
-
Humans
-
Lung Neoplasms / complications
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / mortality
-
Male
-
Middle Aged
-
Patient Reported Outcome Measures*
-
Progression-Free Survival
-
Protein Kinase Inhibitors / administration & dosage*
-
Protein Kinase Inhibitors / adverse effects
-
Quality of Life
-
Quinazolinones / administration & dosage*
-
Quinazolinones / adverse effects
-
Response Evaluation Criteria in Solid Tumors
Substances
-
Protein Kinase Inhibitors
-
Quinazolinones
-
dacomitinib
-
EGFR protein, human
-
ErbB Receptors
-
Gefitinib